From Toshiba America Medical Systems Inc.;
the Ultra™ system was developed to help healthcare providers be more competitive by delivering greater patient comfort and a broad range of clinical capabilities, says Anita Bowler, product manager, MRI Business Unit, Toshiba America Medical Systems Inc With its unique, powerful gradient technology, the Ultra™ performs advanced clinical studies and consistently provides high-resolution images that are typically associated with high field MRI systems. At the same time, the Ultra™ offers a truly open feeling that makes patients more relaxed, especially those with claustrophobic tendencies.

Vasovist™ is an albumin-targeted intravascular contrast agent. It is indicated for contrast enhanced MR angiography (CE-MRA) for the visualization of abdominal or limb vessels in patients with suspected or known vascular disease. After IV injection, Vasovist™ binds reversibly to human albumin in plasma, which results in long-lasting increased relaxivity. Imaging from 5 to 50 min is possible. A small unbound portion is, by glomerular filtration, eliminated by the kidneys.
AngioMARK® was the formerly trade name and MS-325 the research name. Currently the phase III clinical trials are completed to determine its efficacy for peripheral vascular disease and coronary artery disease.
In the U.S., EPIX received an approvable letter from the U.S. Food and Drug Administration (FDA) for Vasovist™ in January 2005. In 2009, Epix Pharmaceuticals has sold the U.S., Canadian and Australian rights for its blood pool agent (now named ABLAVAR™), to Lantheus Medical Imaging, Inc..

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m²), or acute renal insufficiency of any severity due to the hepato-renal syndrome or the liver transplantation period.

See also MRI Safety.

Quick Overview

The saturation effect of inflowing blood in 3D inflow MRA.

Smaller 3D Volume or scans with e.g. tilt optimized nonsaturated excitation. In multi chunk scans TONE decreases this artifact or allows thicker chunks.

Area within a blood vessel where the blood is suddenly accelerated, then rapidly decelerated. This would be commonly seen in blood passing through a vascular stenosis (narrowing), and becomes a factor in MRA.